REGN · Regeneron Pharmaceuticals, Inc.
$632.902026-07-21Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$3692
+483.4% vs market
Base · active
$1394
+120.3% vs market
Bear
$1043
+64.9% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($1043 · $3692) Analysts Range ($641 · $995) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $13.1B | — | 52.9% | 4.6% | $6.6B | −$1.4B | $5.3B | 5.2% | — | 22.8% | $29.1B | $36.71 | — |
| 2024.Q4 | $13.1B | 0.0% | 52.9% | 7.7% | $6.4B | −$1.9B | $4.5B | 6.3% | — | 20.7% | $32.9B | $36.71 | — |
| 2025.Q1 | $14.2B | 8.3% | 44.8% | 9.7% | $5.7B | −$2.8B | $3.0B | 5.4% | — | 16.5% | $36.9B | $40.97 | — |
| 2025.Q4 | $14.2B | 0.0% | 44.8% | 13.9% | $5.5B | −$1.9B | $3.6B | 6.0% | — | 14.5% | $38.6B | $40.97 | — |
| 2026.Q1 | $14.9B | 5.1% | 38.8% | 14.2% | $5.0B | −$2.3B | $2.7B | 5.2% | — | 12.5% | $40.9B | $41.07 | 11.8 |
| italics below = DCF projection · 10yr Rev CAGR: 7.2% |
| 2027.Q1 | $16.3B | +9.6% | 62.0% | 14.8% | $8.6B | −$2.5B | $6.1B | 5.5% | $5.8B | 20.4% | $43.4B | $31.46 | 20.1 |
| 2028.Q1 | $17.9B | +9.8% | 58.4% | 15.4% | $8.9B | −$3.2B | $5.7B | 5.8% | $5.1B | 19.7% | $46.6B | $35.21 | 18.0 |
| 2029.Q1 | $19.4B | +8.3% | 54.8% | 16.0% | $8.9B | −$3.4B | $5.5B | 6.1% | $4.6B | 18.5% | $50.0B | $38.88 | 16.3 |
| 2030.Q1 | $21.1B | +8.5% | 51.2% | 16.5% | $9.0B | −$3.1B | $5.9B | 6.4% | $4.7B | 17.5% | $53.1B | $42.96 | 14.7 |
| 2031.Q1 | $22.7B | +7.8% | 44.0% | 17.1% | $8.3B | −$3.2B | $5.1B | 6.7% | $3.8B | 15.2% | $56.4B | $48.26 | 13.1 |
|
| Term. Yr+ | $31.0B | 4.1% | 44.0% | 20.0% | $10.9B | −$3.4B | $7.5B | 8.6% | $85.7B | 13.1% | — | — | — |
Active scenario IV: $1394 (+120.3% vs market)